BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36809425)

  • 1. The role of [
    Basso Dias A; Mirshahvalad SA; Ortega C; Perlis N; Berlin A; van der Kwast T; Ghai S; Jhaveri K; Metser U; Haider M; Avery L; Veit-Haibach P
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2167-2176. PubMed ID: 36809425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of PSMA PET/MR radiomics for prostate cancer staging.
    Solari EL; Gafita A; Schachoff S; Bogdanović B; Villagrán Asiares A; Amiel T; Hui W; Rauscher I; Visvikis D; Maurer T; Schwamborn K; Mustafa M; Weber W; Navab N; Eiber M; Hatt M; Nekolla SG
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):527-538. PubMed ID: 34255130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of [
    Ghezzo S; Mapelli P; Bezzi C; Samanes Gajate AM; Brembilla G; Gotuzzo I; Russo T; Preza E; Cucchiara V; Ahmed N; Neri I; Mongardi S; Freschi M; Briganti A; De Cobelli F; Gianolli L; Scifo P; Picchio M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2548-2560. PubMed ID: 36933074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective analysis of clinically significant prostate cancer detection with [
    Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between
    Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B
    Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
    Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
    Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts.
    Grahovac M; Spielvogel CP; Krajnc D; Ecsedi B; Traub-Weidinger T; Rasul S; Kluge K; Zhao M; Li X; Hacker M; Haug A; Papp L
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1607-1620. PubMed ID: 36738311
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Niu S; Liu Y; Ding X; Xu Y; Yu H; Feng X; Chang X; Wang H; Li J; Gong H; Ao L; Liu J; Lin M; Wang B; Ma X; Xu B; Zhang X
    Prostate; 2023 Feb; 83(2):142-150. PubMed ID: 36281654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning-based analysis of [
    Cysouw MCF; Jansen BHE; van de Brug T; Oprea-Lager DE; Pfaehler E; de Vries BM; van Moorselaar RJA; Hoekstra OS; Vis AN; Boellaard R
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):340-349. PubMed ID: 32737518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced zoomed diffusion-weighted imaging vs. full-field-of-view diffusion-weighted imaging in prostate cancer detection: a radiomic features study.
    Hu L; Zhou DW; Fu CX; Benkert T; Jiang CY; Li RT; Wei LM; Zhao JG
    Eur Radiol; 2021 Mar; 31(3):1760-1769. PubMed ID: 32935192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta radiomic patterns on serial bi-parametric MRI are associated with pathologic upgrading in prostate cancer patients on active surveillance: preliminary findings.
    Midya A; Hiremath A; Huber J; Sankar Viswanathan V; Omil-Lima D; Mahran A; Bittencourt LK; Harsha Tirumani S; Ponsky L; Shiradkar R; Madabhushi A
    Front Oncol; 2023; 13():1166047. PubMed ID: 37731630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies.
    Basso Dias A; Ghai S; Ortega C; Mirshahvalad SA; Perlis N; Berlin A; Avery L; Veit-Haibach P; van der Kwast T; Metser U
    Clin Nucl Med; 2023 Oct; 48(10):e462-e467. PubMed ID: 37682613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of repeatability of radiomic features derived from PET scans: Results from a
    Werner RA; Habacha B; Lütje S; Bundschuh L; Kosmala A; Essler M; Derlin T; Higuchi T; Lapa C; Buck AK; Pienta KJ; Lodge MA; Eisenberger MA; Markowski MC; Pomper MG; Gorin MA; Frey EC; Rowe SP; Bundschuh RA
    Prostate; 2023 May; 83(6):547-554. PubMed ID: 36632656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
    Bernatz S; Ackermann J; Mandel P; Kaltenbach B; Zhdanovich Y; Harter PN; Döring C; Hammerstingl R; Bodelle B; Smith K; Bucher A; Albrecht M; Rosbach N; Basten L; Yel I; Wenzel M; Bankov K; Koch I; Chun FK; Köllermann J; Wild PJ; Vogl TJ
    Eur Radiol; 2020 Dec; 30(12):6757-6769. PubMed ID: 32676784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer.
    Abdollahi H; Mofid B; Shiri I; Razzaghdoust A; Saadipoor A; Mahdavi A; Galandooz HM; Mahdavi SR
    Radiol Med; 2019 Jun; 124(6):555-567. PubMed ID: 30607868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
    Luining WI; Oprea-Lager DE; Vis AN; van Moorselaar RJA; Knol RJJ; Wondergem M; Boellaard R; Cysouw MCF
    PLoS One; 2023; 18(11):e0293672. PubMed ID: 37943772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of integrated
    Zeng Y; Leng X; Liao H; Jiang G; Chen P
    Prostate Int; 2022 Jun; 10(2):108-116. PubMed ID: 35510079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of quantitative parameters and radiomic features as inputs into machine learning models to predict the Gleason score of prostate cancer lesions.
    Nai YH; Cheong DLH; Roy S; Kok T; Stephenson MC; Schaefferkoetter J; Totman JJ; Conti M; Eriksson L; Robins EG; Wang Z; Chua WY; Ang BWL; Singha AK; Thamboo TP; Chiong E; Reilhac A
    Magn Reson Imaging; 2023 Jul; 100():64-72. PubMed ID: 36933775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.